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The full-text version of the ESC/EACTS Guidelines on myocar-
dial revascularization was adjusted by the Task Force selected
by the Czech Society of Cardiology representing professionals
involved in the medical care of patients with this pathology.
Class IA means the strongest recommendation based on the
level of evidence and strength of recommendation, and class
III means the therapy is not recommended and may be
harmful.
2. Introduction
In 2014, coronary artery bypass grafting (CABG) celebrated
the 50th anniversary of the ﬁrst procedures performed in
1964. Thirteen years later, the ﬁrst percutaneous coronary
intervention (PCI) was performed and PCI has become one of
the most frequently performed therapeutic interventions in
medicine.
3. Scores and risk stratiﬁcation
Myocardial revascularization in the elective setting is appro-
priate when the expected beneﬁts, in terms of survival or
health outcomes (symptoms, functional status, and/or quality
of life), exceed the expected negative consequences of theTable 1 – Risk models to assess short-term (in-hospita
Score Develop ment
cohort
(patients,
des ign )
Patient
inclusion
Coronary
procedures
Number of
variables
Cli nical Anato mi
STS Score n = 774 88 1Multicen tre
01/200 6
–
12/200 6
100%
(i)CABG 40 2
EuroSCORE
II
n =16 82 8
Multicen tre
05/201 0
–
07/201 0
47%
(i)CABG 18 0
ACEF n = 4 55 7Single-cen tre
2001
–
2003
- 3 0
NCDR
CathPCI
181 77 5
Multicen tre
01/200 4
–
03/200 6
100% PCI 8 0
EuroSCORE n =19 03 0Multicen tre
09/199 5
–
11/199 5
64%
(i)CABG 17 0
ACEF = age, creatinine, ejection fraction; (i)CABG = (isolated) co
cular Data Registry; PCI = percutaneous coronary intervention; 
aWhichever occurs last.
bPermanent stroke, renal failure, prolonged ventilation, deep ster
cIf creatinine is 2 mg/dL.procedure. The Heart Team should take into consideration the
coronary artery disease, age, LVEF and comorbidities, patient
preference, and hospital/operator experience.
Numerous models have been developed for risk stratiﬁca-
tion. The limitations of the models restrict the ability to
recommend one speciﬁc risk model (except EuroSCORE II that
should replace EuroSCORE). It is also important to acknowl-
edge that no risk score can accurately predict events in an
individual patient (Tables 1 and 2).
4. Process for decision-making and patient
information
4.1. Patient information and informed consent
Patient information needs to be unbiased, evidence-based, up-
to-date, reliable, accessible, relevant, and consistent with legal
requirements. These recommendations pertain to patients in
stable condition.
4.2. Multidisciplinary decision-making (Heart Team)
The Heart Team, made up of clinical or non-invasive
cardiologists, cardiac surgeons and interventional cardiolo-
gists, provides a balanced, multidisciplinary decision-making
process. Multidisciplinary decision-making in a Heart Team
can minimize specialty bias and prevent self-referral from
interfering with optimal patient care (Table 3).l or 30-day) outcomes.
Outcome Rec omm end ation Vali dation
studies
Calculation
ca l CABG PCI
In-ho spital
or 30-daya
mortali ty,
and in-
hospital
morbidityb
I B 5–10 htt p:// riskc alc.sts .org
In-ho spital
mortali ty IIa B IIb C >10
www.euroscore.org
/calc.html
In-ho spital
or 30-daya
mortality
IIb C IIb C 5–10
[Age /ejection 
fraction (%)]
+ 1c
In-ho spital
mortali ty IIb B <5 -
Ope rative
mortali ty III B III C >50
www.euroscore.org
/calcold.html
ronary artery bypass grafting; NCDR = National Cardiovas-
STS = Society of Thoracic Surgeons.
nal wound infection, re-operation, length of stay, 6 or 14 days.
Table 2 – Risk models to assess medium- to long-term (≥1 year) outcomes.
Score Develop ment
cohort
Patient
inclusion
Coronary
procedures
Number
of variables
Outcome Rec omm end ation Vali dation
studies
Calculation
Cli nical Anato mica l CABG PCI
SYNTAX None, expertopinion
none - 0
11
(3 gene ral,
8 per lesion )
MACC E I B I B >50 www.syntaxsc ore.com
SYNTAX
II
1 80 0
Multicen tre
03/200 5
–
04/200 7
50%
CAB G,
50% PCI
6 12 4-yearmortali ty IIa B IIa B <5 -
ASCERT
CAB G
174 50 6
Multicen tre
01/200 2
–
12/200 7
100%
(i)CABG 23 2
Mortality
>2 year s IIa B <5 -
ASCERT
PCI
206 08 1
Multicen tre
2004
–
2007
100%
PCI 17 2
Mortality
>1 year IIa B <5 -
Logistic
Cli nical
SYNTAX
6 50 8
Multicen tre
03/200 5
–
04-200 7
100%
PCI 3 11
1-year
MACE
and
mortali ty
IIa B <5 -
ASCERT = American College of Cardiology Foundation–Society of Thoracic Surgeons Database Collaboration (ACCF–STS) on
the comparative effectiveness of revascularization strategies; (i) CABG = (isolated) coronary artery bypass grafting;
MACCE = major adverse cardiac and cerebrovascular events; PCI = percutaneous coronary intervention; SYNTAX = synergy
between percutaneous coronary intervention with TAXUS and cardiac surgery.
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Patients with stable coronary artery disease (SCAD) suffering
severe angina (class Canadian Cardiovascular Society (CCS)
Class 3 and those with high-risk anatomy should preferably
undergo revascularization (PCI or CABG) within 2 weeks, and
all other patients within 6 weeks. Complex pathologies in
stable patients should in general not be treated ad hoc, but
discussed by the Heart Team.
5. Strategies for diagnosis: functional testing
and imaging
5.1. Non-invasive tests
The risks of exercise, pharmacological stressors, contrast
agents, invasive procedures, and cumulative ionizing radiation
must be weighed against the risk of disease or delayed
diagnosis. Ischaemia imaging has been regarded the most
appropriate in patients with intermediate pre-test probability
(15–85%).
5.2. Invasive tests
When non-invasive stress imaging is contraindicated, non-
diagnostic, or unavailable, the measurement of fractional ﬂow
reserve (FFR) or coronary ﬂow reserve is helpful during
diagnostic coronary angiography.
5.3. Detection of myocardial viability
The differences in performance between the various imaging
techniques are small and experience and availability com-
monly determine which technique is used (Table 4).6. Revascularization for stable coronary artery
disease
The indications for revascularization are persistence of
symptoms despite medical treatment and/or improvement
of prognosis. Revascularization more effectively relieves
ischaemia and angina, reduces the use of anti-angina drugs,
and improves exercise capacity and quality of life, compared
with medical therapy alone. The extent, location, and severity
of coronary artery obstruction are prognostic factors in
addition to ischaemia and left ventricular function. The
evidence basis for revascularization is derived from several
RCTs. The best current revascularization results achieved with
PCI are with new-generation drug-eluting stents (DES) and for
CABG with maximal use of arterial grafts.
6.1. Revascularization with the use of PCI
The COURAGE trial randomized patients with moderate
disease, no or mild ischaemia and normal LV function, (LM
disease excluded) to PCI with BMS or medical therapy alone. At
a median follow-up of 4.6 years, there were no signiﬁcant
differences in death, myocardial infarction and stroke.
Freedom from angina was signiﬁcantly greater in the PCI
group. The FAME-2 trial was stopped prematurely due to a
highly signiﬁcant difference in favour of FFR-guided PCI over
medical therapy (a composite of death, MI, and urgent
TVR = 4.3% vs. 12.7%, P = 0.001) (Table 5).
6.2. PCI with DES vs. BMS
The major limitation of most of the previous comparisons is
the lack of use of DES offering 50–70% reduction for repeat TVR.
New-generation DES compared with early-generation DES
Table 3 – Multidisciplinary decision pathways, patient informed consent, and timing of intervention.
ACS Multivessel SCAD SCAD with
ad hoc PCI
indication
according to
predeﬁned Heart
Team protocols
Shock STEMI NSTE-ACS
Multidisciplinary
decision making
Not mandatory
during the acute
phase. Mechanical
circulatory
support according
to Heart Team
protocol.
Not mandatory
during the acute
phase.
Not mandatory
during the acute
phase. After
stabilization
recommended as
in stable
multivessel CAD.
Required. Not required.
Informed consent Verbal witnessed
informed consent
or family consent
if possible without
delay.
Verbal witnessed
informed consent
may be sufﬁcient
unless written
consent is legally
required.
Written informed
consent.a
Written informed consent.a Written
informed
consent.a
Time to
revascularization
Emergency: no
delay.
Emergency: no
delay.
Urgency: within
24 h if possible and
no later than 72 h.
For patients with severe
symptoms (CCS 3) and
for those with high-risk
anatomy (left main disease
or equivalent, three-vessel
disease or proximal LAD or
depressed ventricular function),
revascularization (PCI or CABG)
should be performed within
two weeks.
For all other patients with
SCAD, revascularization
(PCI or CABG) should be
performed within six weeks.
Ad hoc.
Procedure Proceed with
intervention based
on best evidence/
availability. Non-
culprit lesions
treated according
to institutional
protocol or Heart
Team decision.
Proceed with
intervention based
on best evidence/
availability. Non-
culprit lesions
treated according
to institutional
protocol or Heart
Team decision.
Proceed with
intervention based
on best evidence/
availability. Non-
culprit lesions
treated according
to institutional
protocol or Heart
Team decision.
Plan most appropriate
intervention allowing enough
time from diagnostic
catheterization to intervention.
Proceed with
intervention
according to
institutional
protocol
deﬁned by
Heart Team.
ACS = acute coronary syndromes; CABG = coronary artery bypass grafting; CCS = Canadian Cardiovascular Society; LAD = left anterior
descending; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; SCAD = stable
coronary artery disease; STEMI = ST-segment elevation myocardial infarction.
a This may not apply to countries that legally do not ask for written informed consent. ESC and EACTS advocate documentation of patient
consent for all revascularization procedures.
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myocardial infarction and stent thrombosis.
6.3. Revascularization with the use of CABG (Table 6)
The superiority of CABG to a strategy of initial medical therapy
demonstrated a survival beneﬁt from CABG in patients with LM
or three-vessel SCAD, particularly when the proximal LAD was
involved. Beneﬁts were greater in those with severe symptoms,
early positive exercise tests, and impaired LV function.
6.4. PCI vs. CABG
Proximal LAD: two meta-analyses reported no signiﬁcant
difference in mortality, myocardial infarction, or stroke.Increase in recurrent angina and repeat revascularization
with PCI is today markedly reduced with DES.
Left main disease: PCI provides at least equivalent results to
CABG for lower-severity LM lesions at up to ﬁve years of follow-
up. The SYNTAX trial (705 patients with predominant distal LM
disease) conﬁrmed comparable primary one-year MACCE (CABG
13.7% vs. PCI 15.8%; P = 0.44). In the PRECOMBAT trial (patients
with LM disease) the primary end-point was 6.7% in the CABG
group and 8.7% in the PCI group, the 1-year composite rate of
death, MI or stroke was 4.0% for CABG and 3.3% for PCI.
Three-vessel coronary artery disease: an historical meta-
analysis reported no difference in mortality between PCI and
CABG. SYNTAX randomly assigned 1800 patients with LM and/
or three-vessel CAD to either an early-generation paclitaxel-
eluting stent or CABG. At 1 year, 12.4% of CABG and 17.8% of PCI
Table 4 – Indications for diagnostic testing in patients with suspected CAD and stable symptoms.
Asymptomatica Symptomatic
Probability of signiﬁcant diseaseb
Low (<15%) Intermediate (15–85%) High (>85%)
Classc Leveld Classc Leveld Classc Leveld Classc Leveld
Anatomical detection of CAD
Invasive angiography III A III A IIb A I A
CT angiographye,f III B III C IIa A III B
Functional test
Stress echo III A III A I A III A
Nuclear imaging III A III A I A III A
Stress MRI III B III C I A III B
PET perfusion III B III C I A III B
Combined or hybrid imaging test
III C III C IIa B III B
CAD = coronary artery disease; CT = computed tomography; MRI = magnetic resonance imaging; PET = positron emission tomography.
a Screening for silent (asymptomatic) myocardial ischaemia may be considered in selected high-risk patients, such as those with diabetes
mellitus.
b Pre-test probability of CAD. Low 0–15%; intermediate 15–85%; high >85% as assessed using the criteria based on ESC Guidelines of SCAD.
c Class of recommendation.
d Level of evidence.
e This refers to CT angiography, not calcium scoring.
f CT is considered to perform best in the lower range of pre-test probability (15–50%).
Table 6 – Graft patency after CABG.
Graft Patency at
1 year
Patency at
4–5 years
Patency at
≥10 years
Saphenous vein graft 75–95% 65–85% 32–71%
Radial artery 92–96% 90% 63–83%
Left IMA >95% 90–95% 88–95%
Right IMA >95% >90% 65–90%
CABG = coronary artery bypass grafting; IMA = internal mammary
artery.
Table 5 – Indications for revascularization in patients with
stable angina or silent ischaemia.
Extent of CAD
(anatomical and/or functional)
Classb Levelc
For prognosis
Left main disease with stenosis >50%a I A
Any proximal LAD stenosis >50%a I A
Two-vessel or three-vessel disease with
stenosis >50%a with impaired LV function
(LVEF <40%)a
I A
Large area of ischaemia (>10% LV) I B
Single remaining patent coronary artery with
stenosis >50%a
I C
For symptoms
Any coronary stenosis >50%a in the presence
of limiting angina or angina equivalent,
unresponsive to medical therapy
I A
CAD = coronary artery disease; FFR = fractional ﬂow reserve;
LAD = left anterior descending coronary artery; LV = left ventricular.
a With documented ischaemia or FFR ≤0.80 for diameter stenosis
<90%.
b Class of recommendation.
c Level of evidence.
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compared with PCI, signiﬁcantly reduced overall MACCE with
respective rates of 26.9% vs. 37.3% (P = 0.001). In patients with
low SYNTAX score (0–22) rates of MACCE were similar (Table 7).
7. Revascularization in non-ST-segment
elevation acute coronary syndromes
7.1. Early invasive vs. conservative strategy
All results supported a routine early invasive strategy with
signiﬁcantly lower incidence of death, MI or rehospitalization.
The beneﬁt was carried mainly in high-risk patients.
7.2. Timing of angiography and intervention
Patients at highest risk (refractory angina, severe heart failure,
cardiogenic shock, life-threatening ventricular arrhythmias, or
haemodynamic instability) should undergo an immediate
(<2 h) invasive evaluation (Tables 8 and 9). The TIMACS trial
revealed 38% lower incidence of death, myocardial infarction, or
stroke at 6 months in high-risk patients with an early (≤24 h) vs.
delayed (≥36 h) strategy. In the ACUITY trial a delay of more than
24 h before PCI was an independent predictor of mortality.
7.3. Type of revascularization
There are no speciﬁc RCTs comparing PCI with CABG. In one-
third of patients, angiography will reveal single-vessel disease,
allowing ad hoc PCI in most cases. The rate of PCI vs. CABG in
multivessel disease is 80% vs. 20%. Culprit-lesion PCI is the ﬁrst
choice. The strategy of multivessel PCI has not been tested;
however, incomplete revascularization is associated with
more 1-year MACCE.
Table 7 – Recommendation for the type of revascularization (CABG or PCI) in patients with SCAD with suitable coronary
anatomy for both procedures and low predicted surgical mortality.
Recommendations according to extent of CAD CABG PCI
Classa Levelb Classa Levelb
One or two-vessel disease without proximal LAD stenosis. IIb C I C
One-vessel disease with proximal LAD stenosis. I A I A
Two-vessel disease with proximal LAD stenosis. I B I C
Left main disease with a SYNTAX score ≤22. I B I B
Left main disease with a SYNTAX score 23–32. I B IIa B
Left main disease with a SYNTAX score >32. I B III B
Three-vessel disease with a SYNTAX score ≤22. I A I B
Three-vessel disease with a SYNTAX score 23–32. I A III B
Three-vessel disease with a SYNTAX score >32. I A III B
CABG = coronary artery bypass grafting; LAD = left anterior descending coronary artery; PCI = percutaneous coronary intervention;
SCAD = stable coronary artery disease.
a Class of recommendation.
b Level of evidence.
Table 8 – Criteria for high risk with indication for invasive
management.
Primary criteria
1. Relevant rise or fall in troponin
2. Dynamic ST- or T-wave changes (symptomatic or silent)
3. GRACE score >140
Secondary criteria
4. Diabetes mellitus
5. Renal insufﬁciency (eGFR <60 mL/min/1.73 m2)
6. Reduced LV function (ejection fraction <40%)
7. Early post-infarction angina
8. Recent PCI
9. Prior CABG
10. Intermediate to high GRACE risk score
(http://www.gracescore.org)
CABG = coronary artery bypass grafting; eGFR = estimated glomeru-
lar ﬁltration rate; GRACE = Global Registry of Acute Coronary Events;
LV = left ventricular; PCI = percutaneous coronary intervention.
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The general consensus is to wait 48–72 h after culprit-lesion
PCI and residual severe CAD. Patients with LM or 3VD involving
the proximal LAD should undergo surgery during hospital stay.Table 9 – Recommendations for invasive evaluation and revas
Recommendations 
Urgent coronary angiography (<2 h) is recommended in patients at very
associated heart failure, cardiogenic shock, life-threatening ventricular
An early invasive strategy (<24 h) is recommended in patients with at le
An invasive strategy (<72 h after ﬁrst presentation) is indicated in patien
or recurrent symptoms.
Non-invasive documentation of inducible ischaemia is recommended in
before deciding on invasive evaluation.
It is recommended to base the revascularization strategy (ad hoc culprit-l
status and comorbidities as well as the disease severity, i.e. distributio
SYNTAX score), according to the local Heart Team protocol.
New-generation DES are indicated for percutanous treatment of signiﬁca
ACS = acute coronary syndromes; CABG = coronary bypass graft surgery; D
coronary syndrome; PCI = percutaneous coronary intervention; SYNTAX =
a Class of recommendation.
b Level of evidence.When there is continuing or recurrent ischaemia, ventricular
arrhythmias, or haemodynamic instability, CABG should be
performed immediately.
7.3.2. PCI
New-generation DES are the default option. Dual antiplatelet
therapy should be maintained for 12 months, irrespective of
stent type.
8. Revascularization in ST-segment elevation
myocardial infarction (Fig. 1)
8.1. PCI
Primary PCI is deﬁned as PCI in the setting of STEMI without
previous ﬁbrinolysis. The door-to-balloon (DTB) time should
be less than 60 min and the infarct-related artery should be
treated during the initial intervention. Multivessel PCI during
STEMI should be considered in patients with cardiogenic shock
in the presence of critical stenoses and persistent ischaemia.
In the PRAMI trial preventive PCI in non-infarct-related
coronary was associated with a reduced risk of death, MI, orcularization in NSTE-ACS.
Classa Levelb
 high ischaemic risk (refractory angina, with
 arrhythmias, or haemodynamic instability).
I C
ast one primary high-risk criterion (Table 6). I A
ts with at least one high-risk criterion (Table 6) I A
 low-risk patients without recurrent symptoms I A
esion PCI/multivessel PCI/CABG) on the clinical
n and angiographic lesion characteristics (e.g.
I C
nt coronary lesions in ACS patients. I A
ES = drug-eluting stent; NSTE-ACS = non-ST-segment elevation acute
 SYNergy between percutaneous coronary intervention with TAXus.
Fig. 1 – Organization of STEMI reperfusion strategies. DI-DO = door-in to door-out time; DTB = door-to-balloon time;
EMS = emergency medical service; FMC = first medical contact; FMCTB = first-medical-contact-to-balloon-time;
PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 3 8 1 – e 4 0 2 e389refractory angina. The radial approach should be preferred
with new-generation DES as default option. Routine use of
thrombus aspiration is not necessary but selective use of
thromboaspiration may improve TIMI 3 ﬂow or prevent stent
thrombosis. Patients presenting between 12 and 48 h, even
pain-free, may beneﬁt from PCI. In patients days after the acute
event only those with recurrent angina or documented residual
ischaemia/viability may be considered for revascularization.
Systematic late PCI of an occluded infarct-related artery in
stable patients has no incremental beneﬁt (Tables 10 and 11).
8.2. Fibrinolysis
Fibrinolytic therapy is recommended within 12 h of symptom
onset in patients without contraindications if primary PCI
cannot be performed by an experienced team within 120 minof FMC, particularly if it can be given pre-hospital and within
the ﬁrst 120 min. Facilitated PCI (reduced or normal dose
ﬁbrinolysis  GPI followed by coronary angiography/PCI) has
shown no advantage over primary PCI alone. Early, routine,
post-thrombolysis angiography with subsequent PCI (3–24 h)
reduced the rates of re-infarction and recurrent ischaemia. In
cases of failed ﬁbrinolysis or re-infarction the patient should
undergo rescue PCI.
8.3. CABG
CABG may be indicated in STEMI patients with unsuitable
anatomy for PCI who have a patent infarct-related artery, in
patients with cardiogenic shock if the coronary anatomy is not
amenable to PCI or for patients with mechanical complica-
tions.
Table 10 – Primary PCI for myocardial reperfusion in STEMI: indications and logistics.
Recommendations Classa Levelb
Indication
Reperfusion therapy is indicated in all patients with time from symptom onset <12 h duration and persistent ST
segment elevation or (presumed) new LBBB.
I A
Primary PCI is the recommended reperfusion therapy over ﬁbrinolysis if performed by an experienced team in a timely
fashion.
I A
In patients with time from symptom onset >12 h, primary PCI is indicated in the presence of continuing ischaemia,
life-threatening arrhythmias or if pain and ECG changes have been stuttering.
I C
Primary PCI is indicated for patients with severe acute heart failure or cardiogenic shock due to STEMI independent from
time delay of symptom onset.
I B
Reperfusion therapy with primary PCI should be considered in patients presenting late (12–48 h) after symptom onset. IIa B
Logistics
It is recommended that the pre-hospital management of STEMI patients be based on regional networks designed to
deliver reperfusion therapy timely and effectively, and to offer primary PCI to as many patients as possible.
I B
It is recommended that all EMSs, emergency departments, coronary care units, and catheterization laboratories have a
written updated STEMI management protocol, preferably shared within geographic networks.
I C
It is recommended that primary PCI-capable centres deliver a 24-h/7-day service and ensure for primary PCI to be
performed as fast as possible and at the latest within 60 min of hospital arrival.
I B
Patients transferred to a PCI-capable centre for primary PCI should bypass the emergency department and be transferred
directly to the catheterization laboratory.
IIa B
ECG = electrocardiogram; EMS = emergency medical service; LBBB = left bundle branch block; PCI = percutaneous coronary intervention;
STEMI = ST-segment elevation myocardial infarction.
a Class of recommendation.
b Level of evidence.
Table 11 – Primary PCI for myocardial reperfusion in STEMI: procedural aspects (strategy and technique).
Recommendations Classa Levelb
Strategy
Primary PCI should be limited to the culprit vessel with the exception of cardiogenic shock and persistent ischaemia after
PCI of the supposed culprit lesion.
IIa B
Staged revascularization of non-culprit lesions should be considered in STEMI patients with multivessel disease in case
of symptoms or ischaemia within days to weeks after primary PCI.
IIa B
Immediate revascularization of signiﬁcant non-culprit lesions during the same procedure as primary PCI of the culprit
vessel may be considered in selected patients.
IIb B
In patients with continuing ischaemia and in whom PCI of the infarct-related artery cannot be performed, CABG should
be considered.
IIa C
Technique
Stenting is recommended (over balloon angioplasty) for primary PCI. I A
New-generation DES are recommended over BMS in primary PCI. I A
Radial access should be preferred over femoral access if performed by an experienced radial operator. IIa A
Thrombus aspiration may be considered in selected patients. IIb A
BMS = bare-metal stent; CABG = coronary artery bypass grafting; DES = drug-eluting stent; PCI = percutaneous coronary intervention;
STEMI = ST-segment elevation myocardial infarction.
a Class of recommendation.
b Level of evidence.
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failure and cardiogenic shock
9.1. Chronic heart failure
Revascularization with CABG or PCI is indicated for symptom-
atic relief of angina pectoris in patients with heart failure. In
the STICH trial surgical revascularization reported signiﬁcant-
ly lower all-cause mortality in favour of CABG conﬁrmed in an
observational cohort during follow-up over 10 years. Early
revascularization in the setting of hibernating myocardium
was associated with improved survival, especially when
the extent of viability exceeded 10% of the myocardium. Therisk–beneﬁt balance for revascularization in patients without
angina/ischaemia or viable myocardium remains uncertain.
Surgical ventricular reconstruction (SVR) may beneﬁt patients
with less-dilated LV and better LVEF, while those with larger
LV and poorer LVEF may do worse (Table 12).
9.2. Cardiogenic shock
Acute myocardial infarction accounts for 75% of cardiogenic
shock (incidence 6–8%). Emergency revascularization (PCI or
CABG) improved long-term survival (SHOCK trial). The use of
IABP had no long-term beneﬁt (IABP-SHOCK II trial). IABP
remains an adjunct for patients with mechanical complica-
tions as a bridge to surgery. LVAD therapy can be implemented
Table 13 – Specific recommendations for revascularization in patients with diabetes.
Recommendations Classa Levelb
In patients presenting with STEMI, primary PCI is recommended over ﬁbrinolysis if it can be performed within
recommended time limits.
I A
In patients with NSTE-ACS, an early invasive strategy is recommended over non-invasive management. I A
In stable patients with multivessel CAD and/or evidence of ischaemia, revascularization is indicated in order to reduce
cardiac adverse events.
I B
In patients with stable multivessel CAD and an acceptable surgical risk, CABG is recommended over PCI. I A
In patients with stable multivessel CAD and SYNTAX score ≤ 22, PCI should be considered as alternative to CABG. IIa B
New-generation DES are recommended over BMS. I A
Bilateral mammary artery grafting should be considered. IIa B
In patients on metformin, renal function should be carefully monitored for 2–3 days after coronary angiography/PCI. I C
BMS = bare-metal stent; CABG = coronary artery bypass grafting; CAD = coronary artery disease; DES = drug-eluting stent; NSTE-ACS = non-ST-
segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.
a Class of recommendation.
b Level of evidence.
Table 12 – Recommendations on revascularizations in patients with chronic heart failure and systolic LV dysfunction
(ejection fraction ≤35%).
Recommendations Classa Levelb
CABG is recommended for patients with signiﬁcant LM stenosis and LM equivalent with proximal stenosis of both LAD
and LCx arteries.
I C
CABG is recommended for patients with signiﬁcant LAD artery stenosis and multivessel disease to reduce death and
hospitalization for cardiovascular causes.
I B
LV aneurysmectomy during CABG should be considered in patients with a large LV aneurysm, if there is a risk of rupture,
large thrombus formation or the aneurysm is the origin of arrhythmias.
IIa C
Myocardial revascularization should be considered in the presence of viable myocardium. IIa B
CABG with surgical ventricular restoration may be considered in patients with scarred LAD territory, especially if a
postoperative LVESV index <70 mL/m2 can be predictably achieved.
IIb B
PCI may be considered if anatomy is suitable, in the presence of viable myocardium, and surgery is not indicated. IIb C
CABG = coronary artery bypass grafting; LAD = left anterior descending; LCx = left circumﬂex; LM = left main; LVESV = left ventricular end-
systolic volume; PCI = percutaneous coronary intervention; SVR = surgical ventricular reconstruction.
a Class of recommendation.
b Level of evidence.
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therapy. Ventricular septal defect is treated by IABP followed by
early surgical repair. Rupture of the free wall, resulting in
tamponade should be salvaged by prompt pericardial drainage
and surgical intervention. Acute mitral regurgitation (rupture of
the papillary muscle) should be treated by immediate surgery.
10. Revascularization in patients with diabetes
10.1. Evidence for myocardial revascularization
10.1.1. Stable coronary artery disease
Among the CABG stratum patients with high-risk angiograph-
ic scores, the 5-year risk of death, myocardial infarction or
stroke was signiﬁcantly lower and ampliﬁed for those assigned
to revascularization, when compared with medical therapy
(24.8% vs. 36.8%, respectively; P = 0.005). No outcome differ-
ence between PCI and medical therapy was observed.
10.1.2. Acute coronary syndromes
Mortality in patients with ACS is two to three times increased in
diabetic patients, compared with non-diabetic. Approximately20–30% of patients with NSTE-ACS have known diabetes,
and at least as many have undiagnosed diabetes or impaired
glucose tolerance. Diabetes presents a secondary indication
for high risk and for invasive management. Compared
with non-diabetic patients, diabetics with STEMI present
later, are more likely to experience haemodynamic instabil-
ity and end-organ damage, and have delayed revasculariza-
tion.
10.2. Type of myocardial revascularization
Taking currently available evidence (FREEDOM, SYNTAX
diabetic subset, CARDia trials) into consideration, CABG is
the revascularization modality of choice among diabetic
patients with multivessel CAD; however, PCI can be consid-
ered as a treatment alternative among diabetic patients with
multivessel disease and low SYNTAX score (≤22). A sensitivity
analysis revealed that the superiority of CABG over early-
generation DES for the endpoint MACCE was most pronounced
among patients with high SYNTAX score, but not signiﬁcant in
those with low SYNTAX score. All RCTs have shown higher
rates of repeat revascularization procedures after PCI com-
pared with CABG, in diabetic patients.
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Compared with BMS, all DES showed a rate of TVR that was
lower by 37–69%. Superior survival observed with bilateral IMA
grafting has been seen not to depend on diabetic status. Indeed,
alternative strategies—including use of the radial artery in
patients with an excessively high risk for sternal complications
(e.g. obese patients)—have been shown to be safe.
10.4. Antithrombotic and anti-diabetic medications
There is no indication that antithrombotic pharmacotherapy
should differ. Because of the risk of lactic acidosis in patients
receiving iodinated contrast media, it is generally stated that
administration of metformin should be suspended before
angiography or PCI, and resumed 48 h later, subject to
adequate renal function (Table 13).
11. Revascularization in patients with chronic
kidney disease
Myocardial revascularization in patients with chronic kidney
disease (CKD) is underused. Current treatment strategies are
based on retrospective analyses of RCTs and data from large
registries.
In patients with moderate chronic kidney disease, CABG is
associated with lower mortality compared with PCI and the
off-pump approach may reduce the risk of perioperative acute
renal failure and/or its progression.
In patients with severe chronic kidney disease and end-
stage renal disease or in haemodialysis, CABG was associated
with lower risks for death and/or myocardial infarction.
Candidates for renal transplantation must be screened for
myocardial ischaemia and revascularization.
Preventive hydration with isotonic saline should be started
approximately 12 h before angiography and continued for at
least 24 h (especially if glomerular ﬁltration rate (GFR) is
<40 mL/min/1.73 m2). The implementation of high-dose
statin before diagnostic catheterization should be considered
(Table 14).Table 14 – Specific recommendations for patients with modera
Recommendations 
CABG should be considered over PCI in patients with multivessel CAD a
proﬁle is acceptable and life expectancy is beyond 1 year.
PCI should be considered over CABG in patients with multivessel CAD a
proﬁle is high or life expectancy is less than 1 year.
It should be considered to delay CABG after coronary angiography until th
subsided.
Off-pump CABG may be considered rather than on-pump CABG. 
New-generation DES are recommended over BMS. 
BMS = bare-metal stent; CABG = coronary artery bypass grafting; CAD =
eluting stent; PCI = percutaneous coronary intervention.
a Class of recommendation.
b Level of evidence.12. Revascularization in patients requiring
valve interventions
12.1. Primary indication for valve interventions
Overall, 40% of patients with valvular heart disease will have
concomitant CAD. Coronary angiography is recommended in
all men >40 years and post-menopausal women. In patients
with severe comorbidities, the Heart Team may opt for
transcatheter valve interventions (TAVI) (Table 15).
12.2. Primary indication for coronary revascularization
Adding mitral valve repair to CABG in patients with LV
dysfunction (LVEF ≤35%) and moderate-to-severe mitral
regurgitation offers better survival than CABG alone. Likewise,
in patients undergoing CABG, aortic valves with moderate
stenosis should be replaced.
13. Associated carotid/peripheral artery
disease
13.1. Associated coronary and carotid artery disease
Up to 40% of patients undergoing carotid endarterectomy
(CEA) have signiﬁcant CAD. CABG carries a greater periproce-
dural risk of stroke compared to PCI, the long-term risk persists
with both treatments. Risk factors for all strokes were age,
smaller body surface area, emergency surgery, previous
stroke, preoperative atrial ﬁbrillation (AF), and on-pump CABG
with hypothermic circulatory arrest. Statins in combination
with beta-blockers have shown a protective effect. In patients
with previous TIA or stroke and the presence of carotid artery
stenosis (50–99% in men; 70–99% in women), CEA performed by
experienced teams may reduce the risk of perioperative stroke
or death. The choice of CEA vs. carotid artery stenting (CAS)
should be based on patient comorbidities, supra-aortic vessel
anatomy, degree of urgency for CABG and local expertise
(Tables 16 and 17).te or severe CKD.
Classa Levelb
nd symptoms/ischaemia whose surgical risk IIa B
nd symptoms/ischaemia whose surgical risk IIa B
e effect of contrast media on renal function has IIa B
IIb B
I B
 coronary artery disease; CKD = chronic kidney disease; DES = drug-
Table 16 – Carotid artery screening before CABG.
Recommendations Classa Levelb
In patients undergoing CABG, Doppler ultrasound scanning is recommended in patients with a history of stroke/TIA or
carotid bruit.
I C
Doppler ultrasound should be considered in patients with multivessel CAD, PAD, or >70 years of age. IIa C
MRI, CT, or digital subtraction angiography may be considered if carotid artery stenosis by ultrasound is >70% and
myocardial revascularization is contemplated.
IIb C
Screening for carotid stenosis is not indicated in patients with unstable CAD requiring emergency CABG with no recent
stroke/TIA.
III B
CABG = coronary artery bypass grafting; CAD = coronary artery disease; CT = computed tomography; MRI = magnetic resonance imaging;
PAD = peripheral artery disease; TIA = transient ischaemic attack.
a Class of recommendation.
b Level of evidence.
Table 15 – Recommendations for combined valvular and coronary interventions.
Recommendations Classa Levelb
Diagnostic modalities
Coronary angiography is recommended before valve surgery in patients with severe valvular heart disease and any of the
following:
 history of CAD
 suspected myocardial ischaemia
 LV systolic dysfunction
 in men aged over 40 years and in post-menopausal women
 ≥1 cardiovascular risk factor for CAD.
I C
Coronary angiography is recommended in the evaluation of secondary mitral regurgitation. I C
CT angiography should be considered before valve surgery in patients with severe valvular heart disease and low
probability for CAD or in whom conventional coronary angiography is technically not feasible or of high risk.
IIa C
Primary valve intervention and coronary revascularization
CABG is recommended in patients with a primary indication for aortic/mitral valve surgery and coronary artery diameter
stenosis >70% in a major epicardial vessel.
I C
CABG should be considered in patients with a primary indication for aortic/mitral valve surgery and coronary artery
diameter stenosis 50–70% in a major epicardial vessel.
IIa C
PCI should be considered in patients with a primary indication to undergo TAVI and coronary artery diameter stenosis
>70% in proximal segments.
IIa C
PCI should be considered in patients with a primary indication to undergo transcatheter mitral valve interventions and
coronary artery diameter stenosis >70% in proximal segments.
IIa C
Primary revascularization and non-coronary intervention
Mitral valve surgery is indicated in patients with severe mitral regurgitation undergoing CABG, and LVEF >30%. I C
Mitral valve surgery should be considered in patients with moderate mitral regurgitation undergoing CABG to improve
symptoms.
IIa B
Repair of moderate-to-severe mitral regurgitation should be considered in patients with a primary indication for CABG
and LVEF ≤35%.
IIa B
Stress testing should be considered in patients with a primary indication for CABG and moderate mitral regurgitation to
determine the extent of ischaemia and regurgitation.
IIa C
Aortic valve surgery should be considered in patients with a primary indication for CABG and moderate aortic stenosis
(deﬁned as valve area 1.0–1.5 cm2 [0.6–0.9 cm2/m2 body surface area] or mean aortic gradient 25–40 mmHg in the
presence of normal ﬂow conditions).
IIa C
CABG = coronary artery bypass grafting; CAD = coronary artery disease; CT = computed tomography; LV = left ventricular; LVEF = left
ventricular ejection fraction; PCI = percutaneous coronary intervention; TAVI = transcatheter aortic valve implantation.
a Class of recommendation.
b Level of evidence.
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Peripheral artery disease (PAD) is an important predictor of
adverse outcome after myocardial revascularization. CABG is
associated with a trend for better survival compared to PCI.
Selected high-risk patients may beneﬁt from staged or
concomitant myocardial revascularization, with options vary-
ing from a one-stage surgical approach to combined PCI and
peripheral endovascular repair or hybrid procedures (Table 18).14. Repeat revascularization and hybrid
procedures
Early graft failure after CABG is reported in up to 12% of grafts,
but only 3% are clinically apparent. Emergency PCI may limit
the extent of MI compared with re-do surgery. Ischaemia after
CABG may be due to progression of disease in native vessels or
late graft failure. Re-do CABG has a two- to fourfold increased
Table 17 – Carotid artery revascularization in patients scheduled for CABG.
Recommendations Classa Levelb
CEA or CAS should be performed by teams achieving a combined death/stroke rate at 30 days of:
<3% in patients without previous neurological symptoms
<6% in patients with previous neurological symptoms.
I A
It is recommended to individualize the indication for carotid revascularization after discussion by a multidisciplinary
team including a neurologist.
I C
The timing of the procedures (synchronous or staged) should be determined by local expertise and clinical presentation,
targeting the most symptomatic territory ﬁrst.
IIa C
In patients with a <6-month history of TIA/stroke
Carotid revascularization is recommended for 70–99% carotid stenosis. I C
Carotid revascularization may be considered for 50–69% carotid stenosis depending on patient-speciﬁc factors and
clinical presentation.
IIb C
In patients with no previous TIA/stroke within 6 months
Carotid revascularization may be considered in men with bilateral 70–99% carotid stenosis or 70–99% carotid stenosis
and contralateral occlusion.
IIb C
Carotid revascularization may be considered in men with 70–99% carotid stenosis and ipsilateral previous silent cerebral
infarction.
IIb C
CABG = coronary artery bypass grafting; CAS = carotid artery stenting; CEA = carotid endarterectomy; TIA = transient ischaemic attack.
The term carotid artery stenosis refers to a stenosis of the extracranial portion of the internal carotid artery, and the degree of stenosis is
according to the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria.
a Class of recommendation.
b Level of evidence.
Table 18 – Management of patients with associated CAD and PAD.
Recommendations Classa Levelb
In patients with ACS, it is recommended to postpone vascular surgery and ﬁrst treat CAD, except when vascular surgery
cannot be delayed due to a life- or limb-threatening condition.
I C
The choice between CABG and PCI should follow the general recommendations for revascularization considering
patterns of CAD, comorbidities, and clinical presentation.
I C
Prophylactic myocardial revascularization before high-risk vascular surgery may be considered in stable patients if they
have persistent signs of extensive ischaemia or are at high cardiac risk.c
IIb B
ACS = acute coronary syndrome; CABG = coronary artery bypass grafting; CAD = coronary artery disease; PAD = peripheral artery disease;
PCI = percutaneous coronary intervention.
a Class of recommendation.
b Level of evidence.
c High cardiac risk (reported cardiac risk often >5%): (1) aortic and other major vascular surgery; (2) peripheral vascular surgery.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 3 8 1 – e 4 0 2e394mortality, PCI is the preferred strategy in patients with patent
left IMA. PCI for SVGs is associated with an increased risk of
distal coronary embolization and intervention via native
artery may be preferred.
Most PCI-related complications (dissections, vessel occlu-
sion, thrombosis and coronary perforation) are successfully
treated in the cath-lab. Urgent surgery is conﬁned to patients
with a large evolving MI that cannot be salvaged percutane-
ously, and to those with iatrogenic cardiac tamponade with
failed pericardiocentesis or recurrent tamponade.
Recurrence of symptoms or ischaemia after PCI is the result
of restenosis, incomplete initial revascularization, or disease
progression. Restenosis should be treated by repeat PCI with
DES, underexpanded stent should be corrected. In patients with
recurrent episodes of diffuse in-stent restenosis associated with
multivessel disease CABG should be considered. Symptomatic
disease progression after PCI (50% of re-interventions) should be
managed similar to patients without previous revasculariza-
tion. Adequate platelet inhibition is minimizing the risk of stent
thrombosis, prasugrel and ticagrelor should be preferred over
clopidogrel for at least 12 months after stent thrombosis.Hybrid myocardial revascularization is combining cardiac
surgery with PCI performed consecutively in a hybrid operat-
ing room, or sequentially on separate occasions. Hybrid
procedures consisting of IMA to LAD and PCI of other
territories appear reasonable when PCI of the LAD is not an
option or when a complete revascularization during CABG
might be associated with an increased risk.
15. Arrhythmias
15.1. Ventricular arrhythmias
Revascularization plays an important role in reducing the
frequency of ventricular arrhythmias in normal and reduced
LV function. Patients with ischaemic LV dysfunction (LVEF
<35%) who are considered for primary preventive ICD
implantation should be evaluated for residual ischaemia
and for potential revascularization targets.
Urgent coronary angiography and revascularization should
be part of the management of patients with electrical storm, as
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ventricular tachycardia.
Approximately 70% of survivors of out-of-hospital cardiac
arrest have CAD, with acute vessel occlusion observed in 50%.
Thus, early coronary angiography and PCI, if appropriate,
should be performed, if no obvious non-cardiac cause of the
arrhythmia is present.
15.2. Atrial arrhythmias
New-onset AF in patients undergoing PCI occurs in 2–6% of
procedures and in one-third of patients undergoing isolated
CABG. Beta-blockers and amiodaron signiﬁcantly decrease
the risk of AF after CABG. Antithrombotic treatment
in patients with AF occurring during or after PCI/CABG
should follow the guidelines for antithrombotic treatment of
AF that occurs outside the setting of PCI/CABG (Section 17).
There are no data on whether prophylactic intraoperative
ablation of AF has an impact on the occurrence of post-
operative AF.
15.3. Concomitant surgical procedures for atrial
ﬁbrillation or stroke treatment
Currently, concomitant surgical LAA obliteration as an adjunct
to anticoagulation may be considered to reduce stroke risk in
CABG patients with a history of AF, but randomized studies are
needed to further clarify this issue.
16. Procedural aspects of coronary artery
bypass grafting
16.1. Surgical procedures
16.1.1. Conduit harvest
16.1.1.1. Saphenous vein harvest. Saphenous vein harvest can
be accomplished using open and endoscopic techniques. If
performed 'open', the 'no-touch' SVG harvesting technique
may reduce graft injury and improve patency.
16.1.1.2. Mammary artery harvesting. Internal mammary
arteries are dissected from the chest wall, either as a pedicle
or as an isolated (skeletonized) vessel.
16.1.2. Coronary vessel
The patency of a bypass graft is inﬂuenced by the character-
istics of the anastomosed vessel, the run-off area, the graft
material, its manipulation, and its construction.
16.1.3. Completeness of revascularization
Anatomical deﬁnition of complete revascularization means
bypass grafting to all epicardial vessels ≥1.5 mm with a
diameter reduction ≥50%.
16.1.4. Construction of central anastomosis
If free conduits (vein grafts, radial artery) are used, additional
central anastomosis for arterial inﬂow into the bypass vessels
is utilized in the majority of cases. In the situation with ahigher atherosclerotic risk proﬁle, grafts are anastomosed
end-to-side in a Y- or T-shaped conﬁguration to the IMAs.
16.1.5. Bypass grafts
The long-term beneﬁt of CABG is maximized with the use of
arterial grafts, speciﬁcally the IMA. Available grafts include the
IMA, radial, and seldom used gastroepiploic arteries.
16.1.6. On-pump and off-pump procedures
For most patients and surgeons, on-pump CABG provides the
best or equal short- and long-term outcomes.
16.1.7. Minimally invasive procedures
Minimally invasive direct coronary artery bypass may repre-
sent an attractive alternative to a sternotomy (Table 19).
16.2. Reporting perioperative outcome
Perioperative reporting of outcome after CABG procedures
should be done on a risk-adjusted basis.
17. Procedural aspects of percutaneous
coronary intervention
17.1. Percutaneous coronary intervention devices
Balloon angioplasty might be an option in small vessels
(<2.0 mm). Fully covered stents can be life-saving in the rare
event of coronary perforation. Early-generation DES potently
reduced angiographic restenosis and ischaemia driven TVR, but
with concerns for very late stent thrombosis. New-generation
DES (thin-strut, metallic platforms, limus-based antiprolifera-
tive drugs from durable or biodegradable polymers or polymer-
free surface) increased efﬁcacy and safety leading to unrestrict-
ed use in patients with CAD including diabetes, multivessel and
LM disease, acute myocardial infarction, SVG, restenotic lesions,
chronic total occlusions and also in patients who require
anticoagulation or undergo non-cardiac surgery. Bioresorbable
stents dissolve over time (several months to 2 years) and may
restore the vasomotion with late lumen enlargement (conﬁr-
mation in large-scale RCTs is required). Drug-coated balloons
may be an option for DES restenosis or for small vessels.
Rotational atherectomy might be required in tight and calciﬁed
lesions to allow subsequent passage of stents.
17.2. Adjunctive invasive diagnostic tools
Intravascular ultrasound is used for: accurate measurements
(plaque burden, plaque composition by ‘‘virtual histology’’),
optimizing stent expansion (a threshold of 5.0–5.5 mm2), in
patients with stent failure (malapposition, restenosis, stent
thrombosis). In the LM disease IVUS-guided stent implanta-
tion improved survival. Optical coherence tomography is more
accurate than IVUS for assessing neointimal thickness, strut
apposition, subtle morphological details (malapposition,
thrombus, plaque prolapse, residual dissection, coverage, in-
stent restenosis, stent fracture, thrombosis) as well as early
stages of cardiac allograft vasculopathy. Pressure-derived
fractional ﬂow reserve (FFR) validated the cut-off ﬁgure of
Table 19 – Procedural aspects of CABG.
Recommendations Classa Levelb
It is recommended to perform procedures in a hospital structure and by a team specialized in cardiac surgery, using
written protocols.
I B
Endoscopic vein harvesting should be considered to reduce the incidence of leg wound complications. IIa A
Routine skeletonized IMA dissection should be considered. IIa B
Skeletonized IMA dissection is recommended in patients with diabetes or when bilateral IMAs are harvested. I B
Complete myocardial revascularization is recommended. I B
Arterial grafting with IMA to the LAD system is recommended. I B
Bilateral IMA grafting should be considered in patients <70 years of age. IIa B
Use of the radial artery is recommended only for target vessels with high-degree stenosis. I B
Total arterial revascularization is recommended in patients with poor vein quality independently of age. I C
Total arterial revascularization should be considered in patients with reasonable life expectancy. IIa B
Minimization of aortic manipulation is recommended. I B
Off-pump CABG should be considered for subgroups of high-risk patients in high-volume off-pump centres. IIa B
Off-pump CABG and/or no-touch on-pump techniques on the ascending aorta are recommended in patients with
signiﬁcant atherosclerotic disease of the ascending aorta in order to prevent perioperative stroke.
I B
Minimally invasive CABG should be considered in patients with isolated LAD lesions. IIa C
Electrocardiogram-triggered CT scans or epiaortic scanning of the ascending aorta should be considered in patients over
70 years of age and/or with signs of extensive generalized atherosclerosis.
IIa C
Routine intraoperative graft ﬂow measurement should be considered. IIa C
CABG = coronary artery bypass grafting; CT = computed tomography; IMA = internal mammary artery; LAD = left anterior descending.
a Class of recommendation.
b Level of evidence.
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trial demonstrated that, in patients with SCAD, FFR-guided PCI
using DES resulted in less need for urgent revascularization
than with medical treatment (Table 20).
17.3. Speciﬁc lesion subsets
Drug eluting stents are the default devices for all lesions.
Bifurcation anatomy may have dynamic variability during PCI
(plaque shift, dissection, side-branch occlusion). Despite a
variety of different stenting techniques (T-stenting, V-stent-
ing, crush and its modiﬁcations, culotte, etc.) stent implanta-
tion in the main vessel only, followed by provisional balloon
angioplasty with or without stenting of the side branchTable 20 – Recommendations for the clinical value of
intracoronary diagnostic techniques.
Recommendations Classa Levelb
FFR to identify haemodynamically relevant
coronary lesion(s) in stable patients when
evidence of ischaemia is not available.
I A
FFR-guided PCI in patients with multivessel
disease.
IIa B
IVUS in selected patients to optimize stent
implantation.
IIa B
IVUS to assess severity and optimize treatment
of unprotected left main lesions.
IIa B
IVUS or OCT to assess mechanisms of stent
failure.
IIa C
OCT in selected patients to optimize stent
implantation.
IIb C
FFR = fractional ﬂow reserve; IVUS = intravascular ultrasound;
OCT = optical coherence tomography; PCI = percutaneous coronary
intervention.
a Class of recommendation.
b Level of evidence.(with 'kissing' balloon dilation when two stents are required)
seems preferred. Left-main lesions require special attention to
adequate sizing and deployment (IVUS). Ostial disease is
ﬁbrotic, calciﬁed, and relatively rigid. Aorto-ostial disease is
resistant to dilation. Chronic total coronary occlusions (TIMI 0
ﬂow and duration of ≥3 months) should be treated in the
presence of symptoms or objective evidence of viability/
ischaemia in the territory of the occluded artery. Successfully
revascularized CTOs confer a long-term survival advantage,
better relief of angina and functional status.
18. Antithrombotic treatments
Patients should be instructed not to prematurely discontinue
oral antiplatelet therapy after stenting.
18.1. Percutaneous coronary intervention in stable
coronary artery disease
18.1.1. Oral antiplatelet therapy
Dual antiplatelet therapy includes a 150–300 mg oral loading
dose of acetylsalicylic acid (ASA) (or 80–150 mg i.v.) followed by
75–100 mg per os (p.o.) daily plus a clopidogrel 300–600 mg
loading dose followed by 75 mg daily. A loading dose of 600 mg
or more is recommended in patients scheduled for elective PCI
if coronary anatomy is known.
18.1.2. Intravenous antiplatelet therapy
Recent trials did not demonstrate additional beneﬁt from GP
IIb/IIIa inhibitors after a clopidogrel loading dose of 600 mg.
18.1.3. Anticoagulation
Enoxaparin (0.5 mg/kg i.v. bolus) or unfractionated heparin
(UFH) with an i.v. bolus of 70–100 U/kg remains the standard
anticoagulant treatment for elective PCI. Bivalirudin might be
Table 21 – Recommendations for antithrombotic treatment in SCAD patients undergoing PCI.
Recommendations for PCI Classa Levelb
Pretreatment with antiplatelet therapy
Treatment with 600 mg clopidogrel is recommended in elective PCI patients once anatomy is known and decision to
proceed with PCI preferably 2 h or more before the procedure.
I A
Pretreatment with clopidogrel may be considered in patients with high probability for signiﬁcant CAD. IIb C
In patients on a maintenance dose of 75 mg clopidogrel, a new loading dose of 600 mg or more may be considered once
the indication for PCI is conﬁrmed.
IIb C
Antiplatelet therapy during PCI
ASA is indicated before elective stenting. I B
ASA oral loading dose of 150–300 mg (or 80–150 mg i.v.) is recommended if not pre-treated. I C
Clopidogrel (600 mg loading dose or more, 75 mg daily maintenance dose) is recommended for elective stenting. I A
GP IIb/IIIa antagonists should be considered only for bail-out. IIa C
Antiplatelet therapy after stenting
DAPT is indicated for at least 1 month after BMS implantation. I A
DAPT is indicated for 6 months after DES implantation. I B
Shorter DAPT duration (<6 months) may be considered after DES implantation in patients at high bleeding risk. IIb A
Life-long single antiplatelet therapy, usually ASA, is recommended. I A
Instruction of patients about the importance of complying with antiplatelet therapy is recommended. I C
DAPT may be used for more than 6 months in patients at high ischaemic risk and low bleeding risk. IIb C
Anticoagulant therapy
Unfractionated heparin 70–100 U/kg. I B
Bivalirudin (0.75 mg/kg bolus, followed by 1.75 mg/kg/h for up to 4 h after the procedure) in case of heparin-induced
thrombocytopaenia.
I C
Bivalirudin (0.75 mg/kg bolus, followed by 1.75 mg/kg/h during the procedure) in patients at high bleeding risk. IIa A
Enoxaparin i.v. 0.5 mg/kg. IIa B
ASA = acetylsalicylic acid; BMS = bare-metal stent; CAD = coronary artery disease; DAPT = dual antiplatelet therapy; DES = drug-eluting stent; GP =
glycoprotein; i.v. = intravenous; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; SCAD = stable coronary artery disease.
a Class of recommendation.
b Level of evidence.
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(Table 21).
18.2. Non-ST-segment elevation acute coronary
syndrome
18.2.1. Oral antiplatelet therapy
Dual antiplatelet therapy includes ASA with an oral loading
dose of 150–300 mg (or 80–150 mg i.v.), followed by 75–100 mg
p.o. daily, and a P2Y12-receptor antagonist.
18.2.1.1. Prasugrel and ticagrelor. Prasugrel (60 mg loading
and 10 mg daily maintenance dose) is a prodrug that
irreversibly blocks the P2Y12 platelet receptor. Based on the
TRITON-TIMI 38 trial, in diabetic patients and patients without
higher bleeding risk, prasugrel is more effective and as safe as
clopidogrel. Prasugrel should be considered in patients who
present with stent thrombosis but is contraindicated in
patients with prior stroke or TIA and generally not recom-
mended for patients of ≥75 years of age.
Ticagrelor [180 mg loading dose; 90 mg b.i.d. (twice daily)
daily maintenance dose] is a reversibly binding P2Y12
inhibitor with a plasma half-life of approximately 6–12 h. In
the PLATO Trial, ticagrelor was superior to clopidogrel in the
composite ischaemic endpoint (HR 0.84) and mortality (HR
0.79). The rate of TIMI major non-CABG-related bleeding was
higher (HR 1.25).
18.2.1.2. Clopidogrel. Clopidogrel is a prodrug leading to an
irreversible blockade of the P2Y12 receptor. Based on the
CURRENT-OASIS 7 ﬁndings, 600 mg loading dose and 150 mgmaintenance dose in the ﬁrst week may be considered only
when prasugrel and ticagrelor are not available or if they are
contraindicated.
18.2.2. Intravenous antiplatelet therapy
Overall, no evidence for an additional beneﬁt of routine
upstream use of GP IIb/IIIa inhibitors.
18.2.3. Anticoagulation
A general rule is to avoid crossover between antithrombins
(with the exception of adding UFH to fondaparinux)—
especially between UFH and low-molecular-weight heparin
(LMWH), and to discontinue antithrombins after PCI except in
speciﬁc situations. Beneﬁt of enoxaparin over UFH in reducing
mortality and bleeding complications was recently reported in
a meta-analysis (Table 22).
18.3. ST-segment elevation myocardial infarction
Patients undergoing primary PCI should receive a combina-
tion of DAPT with ASA and a P2Y12 receptor blocker as early
as possible before angiography, and a parenteral anticoagu-
lant.
18.3.1. Oral antiplatelet therapy
An oral loading dose of ASA 150–300 mg (or i.v. 80–150 mg)
followed by 75–100 mg p.o. daily should be given in combination
with the preferred P2Y12 inhibitors, prasugrel (60 mg p.o.
loading dose; 10 mg maintenance dose) or ticagrelor (180 mg
p.o. loading dose; 90 mg maintenance dose b.i.d.). Importantly,
the more potent agents (prasugrel and ticagrelor) should not be
Table 22 – Recommendations for antithrombotic treatment in patients with NSTE-ACS undergoing PCI.
Recommendations Classa Levelb
Antiplatelet therapy
ASA is recommended for all patients without contraindications at an initial oral loading dose of 150–300 mg (or 80–150 mg
i.v.), and at a maintenance dose of 75–100 mg daily long-term regardless of treatment strategy.
I A
A P2Y12 inhibitor is recommended in addition to ASA, and maintained over 12 months unless there are contraindications
such as excessive risk of bleeding. Options are:
I A
 Prasugrel (60 mg loading dose, 10 mg daily dose) in patients in whom coronary anatomy is known and who are proceeding
to PCI if no contraindication.
I B
 Ticagrelor (180 mg loading dose, 90 mg twice daily) for patients at moderate-to-high risk of ischaemic events, regardless of
initial treatment strategy including those pre-treated with clopidogrel if no contraindication.
I B
 Clopidogrel (600 mg loading dose, 75 mg daily dose), only when prasugrel or ticagrelor are not available or are contraindicated. I B
GP IIb/IIIa antagonists should be considered for bail-out situation or thrombotic complications. IIa C
Pre-treatment with prasugrel in patients in whom coronary anatomy not known, is not recommended. III B
Pre-treatment with GP IIb/IIIa antagonists in patients in not known, is not recommended. III A
Anticoagulant therapy
Anticoagulation is recommended for all patients in addition to antiplatelet therapy during PCI. I A
The anticoagulation is selected according to both ischaemic and bleeding risks, and according to the efﬁcacy–safety proﬁle of
the chosen agent.
I C
Bivalirudin (0.75 mg/kg bolus, followed by 1.75 mg/kg/h for up to 4 h after the procedure) is recommended as alternative to
UFH plus GP IIb/IIIa receptor inhibitor during PCI.
I A
UFH is recommended as anticoagulant for PCI if patients cannot receive bivalirudin. I C
In patients on fondaparinux (2.5 mg daily s.c.), a single bolus UFH (85 IU/kg, or 60 IU/kg in the case of concomitant use of GP
IIb/IIIa receptor inhibitors) is indicated during PCI.
I B
Enoxaparin should be considered as anticoagulant for PCI in patients pre-treated with subcutaneous enoxaparin. IIa B
Discontinuation of anticoagulation should be considered after an invasive procedure unless otherwise indicated. IIa C
Crossover of UFH and LMWH is not recommended. III B
ASA = acetylsalicylic acid; GP = glycoprotein; i.v. = intravenous; LMWH = low-molecular-weight heparin; NSTE-ACS = non-ST-segment eleva-
tion acute coronary syndrome; PCI = percutaneous coronary intervention; UFH = unfractionated heparin.
a Class of recommendation.
b Level of evidence.
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moderate-to-severe liver disease. If not available or contra-
indicated, clopidogrel 600 mg p.o. should be given instead.
18.3.2. Intravenous antiplatelet therapy
It remains unclear whether the clinical beneﬁt observed in On-
TIME-2 (high-dose tiroﬁban upstream vs. downstream provi-
sional) are due to upstream vs. downstream administration or
due to systematic vs. provisional administration. Time from
symptom onset to study drug in overall negative trial FINESSE
trial (abciximab upstream vs. in-cathlab) was twice as long as in
On-TIME 2. GP IIb/IIIa inhibitors as bail-out therapy appears
reasonable.
18.3.3. Anticoagulation
Recent trials comparing bivalirudin with UFH without system-
atic use of GPIIb/IIIa antagonists showed similar effectivity and
uphold concerns over an excess risk for acute stent thrombosis
with bivalirudin, while differences in major bleeding are small.
Enoxaparin [0.5 mg/kg i.v. followed by subcutaneous (s.c.)
treatment] was superior to UFH, and fondaparinux is not
recommended (Table 23).
18.4. Points of interest and special conditions
18.4.1. Pre-treatment with P2Y12 inhibitors
Clopidogrel pre-loading in NSTE-ACS and STEMI was associ-
ated with a signiﬁcant reduction in major cardiovascular
events. Prasugrel pre-loading in NSTEMI is based on the
ACCOAST study not recommended. The risk–beneﬁt ratio ofpretreatment using ticagrelor prior to diagnostic coronary
angiography is not known.
18.4.2. Intravenous P2Y12 inhibitors
Cangrelor is a direct reversible, short-acting (half-life 3 min)
P2Y12 inhibitor that showed lower rates of PCI periprocedural
thrombotic complications (OR 0.81) and of stent thrombosis
(OR 0.59) with no difference in (GUSTO) major bleeding
compared to LD of clopidogrel.
18.4.3. Anticoagulation after percutaneous coronary
intervention in acute coronary syndrome patients
Low-dose rivaroxaban (2.5 mg twice daily) may be considered
in patients who receive ASA and clopidogrel after ACS,
particularly after STEMI. The role of direct oral anticoagulants
in combination with DAPT in secondary prevention of ACS is
promising but requires further study.
18.4.4. Anticoagulation during percutaneous coronary
intervention in patients on oral anticoagulation
In elective PCI, no additional anticoagulation is needed if the
international normalized ratio (INR) is 2.5. Radial access
should be the preferred choice. Glycoprotein IIb/IIIa inhibitors
should generally be avoided.
18.4.5. Antithrombotic therapy after percutaneous coronary
intervention in patients requiring oral anticoagulation
Triple therapy, consisting of ASA, clopidogrel, and (N)OAC
after PCI, should only be given if a compelling indication exists
and should be limited in duration (Table 24).
Table 24 – Recommendations for antithrombotic treatment in patients undergoing PCI who require oral anticoagulation.
Recommendations Classa Levelb
In patients with a ﬁrm indication for oral anticoagulation (e.g. atrial ﬁbrillation with CHA2DS2-VASc score 2, venous
thromboembolism, LV thrombus, or mechanical valve prosthesis), oral anticoagulation is recommended in addition to
antiplatelet therapy.
I C
New-generation DES are preferred over BMS among patients requiring oral anticoagulation if bleeding risk is low (HAS-BLED 2). IIa C
In patients with SCAD and atrial ﬁbrillation with CHA2DS2-VASc score 2 at low bleeding risk (HAS-BLED 2), initial triple
therapy of (N)OAC and ASA (75–100 mg/day) and clopidogrel 75 mg/day should be considered for a duration of at least one
month after BMS or new-generation DES followed by dual therapy with (N)OAC and aspirin 75–100 mg/day or clopidogrel
(75 mg/day) continued up to 12 months.
IIa C
DAPT should be considered as alternative to initial triple therapy for patients with SCAD and atrial ﬁbrillation with a
CHA2DS2-VASc score ≤1.
IIa C
In patients with ACS and atrial ﬁbrillation at low bleeding risk (HAS-BLED 2), initial triple therapy of (N)OAC and ASA
(75–100 mg/day) and clopidogrel 75 mg/day should be considered for a duration of 6 months irrespective of stent type
followed by (N)OAC and aspirin 75–100 mg/day or clopidogrel (75 mg/day) continued up to 12 months.
IIa C
In patients requiring oral anticoagulation at high bleeding risk (HAS BLED 3), triple therapy of (N)OAC and ASA (75–100 mg/day)
and clopidogrel 75 mg/day should be considered for a duration of one month followed by (N)OAC and aspirin 75–100 mg/day
or clopidogrel (75 mg/day) irrespective of clinical setting (SCAD or ACS) and stent type (BMS or new-generation DES).
IIa C
Dual therapy of (N)OAC and clopidogrel 75 mg/day may be considered as an alternative to initial triple therapy in selected
patients.
IIb B
The use of ticagrelor and prasugrel as part of initial triple therapy is not recommended. III C
Anticoagulation therapy after PCI in ACS patient
In selected patients who receive ASA and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily) may be considered in the
setting of PCI for ACS if the patient is at low bleeding risk.
IIb B
Anticoagulation during PCI in patients on oral anticoagulation
It is recommended to use additional parenteral anticoagulation, regardless of the timing of the last dose of (N)OAC. I C
Periprocedural parenteral anticoagulants (bivalirudin, enoxaparin or UFH) should be discontinued immediately after primary
PCI.
IIa C
ACS = acute coronary syndrome; ASA = acetylsalicylic acid; BMS = bare-metal stent; CHA2DS2-VASc = Cardiac failure, Hypertension, Age ≥75
[Doubled], Diabetes, Stroke [Doubled]–Vascular disease, Age 65–74 and Sex category [Female]); DAPT = dual antiplatelet therapy; DES = drug-
eluting stent; (N)OAC = (non-vitamin K antagonist) oral anticoagulant; HAS-BLED = hypertension, abnormal renal/liver function, stroke,
bleeding history or predisposition, labile INR, elderly, drugs/alcohol; INR = international normalized ratio; LV = left ventricular; PCI = percu-
taneous coronary intervention; SCAD = stable coronary artery disease; UFH = unfractionated heparin.
a Class of recommendation.
b Level of evidence.
Table 23 – Recommendations for antithrombotic treatment in patients with STEMI undergoing primary PCI.
Recommendations Classa Levelb
Antiplatelet therapy
ASA is recommended for all patients without contraindications at an initial oral loading dose of 150–300 mg
(or 80–150 mg i.v.) and at a maintenance dose of 75–100 mg daily long-term regardless of treatment strategy.
I A
A P2Y12 inhibitor is recommended in addition to ASA and maintained over 12 months unless there are contraindications
such as excessive risk of bleeding. Options are:
I A
Prasugrel (60 mg loading dose, 10 mg daily dose) if no contraindication. I B
Ticagrelor (180 mg loading dose, 90 mg twice daily) if no contraindication. I B
Clopidogrel (600 mg loading dose, 75 mg daily dose), only when prasugrel or ticagrelor are not available or are contraindicated. I B
It is recommended to give P2Y12 inhibitors at the time of ﬁrst medical contact. I B
GP IIb/IIIa inhibitors should be considered for bail-out or evidence of no-reﬂow or a thrombotic complication. IIa C
Upstream use of a GP IIb/IIIa inhibitor (vs. in-lab use) may be considered in high-risk patients undergoing transfer for primary
PCI.
IIb B
Anticoagulants
Anticoagulation is recommended for all patients in addition to antiplatelet therapy during PCI. I A
The anticoagulation is selected according to both ischaemic and bleeding risks, and according to the efﬁcacy–safety proﬁle
of the chosen agent.
I C
Unfractionated heparin: 70–100 U/kg i.v. bolus when no GP IIb/IIIa inhibitor is planned; 50–70 U/kg i.v. bolus with GPIIb/IIIa
inhibitor.
I C
Bivalirudin 0.75 mg/kg i.v. bolus followed by i.v. infusion of 1.75 mg/kg/h for up to 4 h after the procedure. IIa A
Enoxaparin i.v. 0.5 mg/kg with or without GP IIb/IIIa inhibitor. IIa B
ASA = acetylsalicylic acid; GP = glycoprotein; i.v. = intravenous; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation
myocardial infarction.
a Class of recommendation.
b Level of evidence.
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Fig. 2 – Algorithm for pre-operative management of patients
under dual antiplatelet therapy.
Table 25 – Antithrombotic drugs dose adjustment in patients with CKD.
Recommendations
ASA No dose adjustment.
Clopidogrel No dose adjustment.
Prasugrel No dose adjustment. No experience with end-stage renal disease/dialysis.
Ticagrelor No dose adjustment. No experience with end-stage renal disease/dialysis.
Enoxaparin No adjustment needed for i.v. use in particular for PCI. Dose adjustment for subcutaneous injection in patients
with creatinine clearance <30 mL/min: half dose.
Unfractionated heparin No adjustment of bolus dose.
Fondaparinux Contra-indicated in patients with severe renal impairment (GFR <20 mL/min).
Bivalirudin  In patients with moderate renal insufﬁciency (GFR 30–59 mL/min) a lower initial infusion rate of 1.4 mg/kg/h
should be given.
 In patients with severe renal insufﬁciency (GFR <30 mL/min) bivalirudin should not be used.
 No reduction in the bolus dose is needed.
Abciximab No speciﬁc recommendation. Careful consideration of bleeding risk.
Eptiﬁbatide  In patients with moderate renal insufﬁciency (GFR ≥30 to <50 mL/min), an i.v. bolus of 180 mg/kg should be
administered, followed by a continuous infusion dose of 1.0 mg/kg/min for the duration of therapy.
 In patients with severe renal insufﬁciency (GFR <30 mL/min) eptiﬁbatide is contra-indicated.
Tiroﬁban In patients with severe renal insufﬁciency (GFR <30 mL/min) the infusion dose should be reduced to 50%
(0.05 mcg/kg/min).
ASA = acetylsalicylic acid; CKD = chronic kidney disease; GFR = glomerular ﬁltration rate; i.v. = intravenous; o.d. = omni diem (every day); s.c.
= subcutaneous; PCI = percutaneous coronary intervention.
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percutaneous coronary intervention
It is recommended that DAPT be administered for at least 1
month after BMS implantation in SCAD, for 6 months after
new-generation DES implantation in SCAD, and for up to 1 year
in patients after ACS, irrespective of revascularization strate-
gy.
18.4.7. Drug interactions: a clopidogrel-related topic
Pharmacodynamic studies—but not clinical outcome stud-
ies—support the use of newer proton pump inhibitors such as
pantoprazole.
18.4.8. Renal dysfunction
Patients with CKD should receive the same ﬁrst-line treat-
ment; thereafter, dose adaptation with respect to kidney
function is essential (Table 25). In PLATO study, ticagrelor was
particularly effective in CKD patients.
18.4.9. Surgery in patients on dual antiplatelet therapy
(Fig. 2)
It is recommended that elective non-cardiac surgery be
delayed until completion of the full course of recommended
and that surgery be performed without discontinuation
of aspirin. In patients with high-to-very-high bleeding
risk, clopidogrel should be discontinued 5 days before,
prasugrel 7 days, ticagrelor 5 days. Withdrawal of P2Y12
inhibitors is not recommended in high-risk cohorts, such
as those with continuing ischaemia and high-risk anatomy.
The substitution of DAPT with LMWH or UFH is ineffective.
18.4.10. Antiplatelet therapy monitoring and genetic testing
Platelet function testing or genetic testing may be considered
in speciﬁc high-risk situations (e.g. history of stent thrombo-
sis; compliance issue; suspicion of resistance; high bleeding
risk).18.4.11. Patients with hypersensitivity to acetylsalicylic acid
In patients with ASA hypersensitivity, and in whom ASA
therapy is necessary, a rapid desensitization procedure may be
performed.
18.4.12. Heparin-induced thrombocytopaenia
Bivalirudin or argatroban, hirudin, lepirudin, and danaparoid
have to be used.
Table 26 – Long-term medical therapy after myocardial revascularization to improve prognosis and recommendations for
lifestyle changes and participation in cardiac rehabilitation programmes.
Recommendations Classa Levelb
Coronary artery disease
Statin therapy with an LDL-C goal <70 mg/dL (<1.8 mmol/L) is indicated to start and continue in all patients with CAD
after revascularization, unless contraindicated.
I A
Low-dose ASA (75–100 mg/day) is recommended in all patients with CAD.c I A
In patients who cannot tolerate ASA, clopidogrel is recommended as an alternative. I B
ACE inhibitors are recommended in all patients with CAD if there is presence of other conditions (e.g. heart failure,
hypertension or diabetes). ARBs are an alternative, if ACE inhibitors are not tolerated.
I A
All patients should be advised on lifestyle changes (including smoking cessation, regular physical activity, and a healthy
diet).
I A
Participation in a cardiac rehabilitation programme to modify lifestyle habits and increase adherence to treatment
should be considered for all patients requiring hospitalization or invasive intervention after an acute ischaemic event
or after coronary bypass surgery.
IIa A
Coronary artery disease and hypertension
A systolic blood pressure goal <140 mmHg should be considered in patients with CAD. IIa A
A DBP goal of <90 mmHg is recommended in all patients. In patients with diabetes a DBP goal <85 mmHg is
recommended.
I A
Coronary artery disease and type 2 diabetes
A target for HbA1c of <7.0% is recommended, which is particularly well established for the prevention of microvascular
disease.
I A
Coronary artery disease and chronic heart failure
It is recommended to start and continue ACE-inhibitors in all patients with heart failure or myocardial infarction with
LVEF <40%, unless contraindicated.
I A
ARBs are indicated in patients who are intolerant of ACE inhibitors and have heart failure or myocardial infarction with
LVEF <40%.
I A
Beta-blocker therapy is indicated in all patients with heart failure or LV dysfunction, unless contraindicated. I A
Aldosterone receptor antagonist therapy is indicated in patients with persisting symptoms (NYHA class II–IV) and an EF
<35%, despite treatment with an ACE inhibitor (or an ARB) and a beta-blocker.
I A
Ivabradine should be considered to reduce the risk of hospitalization for heart failure in patients in sinus rhythm with an
EF <35%, a heart rate >70 b.p.m., and persisting symptoms (NYHA class II–IV) despite treatment with an evidence-
based dose of a beta-blocker (or maximum tolerated), ACE inhibitor (or ARB), and a mineralocorticoid receptor
antagonist (or ARB).
IIa B
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; ASA = acetylsalicylic acid; b.p.m. = beats per minute; CAD = cor-
onary artery disease; DBP = diastolic blood pressure; EF = ejection fraction; HbA1c = glycated haemoglobin A1c; LDL-C = low-density lipoprotein
cholesterol; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; PCI = percutaneous coronary intervention.
a Class of recommendation.
b Level of evidence.
c For antithrombotic therapy in addition to ASA after PCI.
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revascularization procedures
Surgeons' case volume, as a continuous variable, is inversely
related to operative mortality (adjusted OR 1.36). The inﬂuence
of the hospital is lower (adjusted OR 1.13). American College of
Cardiology Foundation/American Heart Association (ACCF/
AHA) guidelines on CABG surgery provide a IIb recommenda-
tion that cardiac surgery programmes with less than 125 CABG
procedures annually be afﬁliated with high-volume tertiary
centres [level of evidence C].
Hospital case volumes of <400 PCIs per year and operator
case volumes of <75 PCIs per year were associated with
impaired outcomes. The best outcomes are obtained with
high-volume operators practising in high-volume institutions.
In the case of primary PCI, it is recommended that, annually,
operators should perform at least 75 elective procedures and
ideally 11 primary PCI procedures in high-volume institutions.A special training in interventional cardiology has been
proposed by the European Association for Percutaneous
Cardiovascular Interventions (EAPCI).
20. Medical therapy, secondary prevention,
and strategies for follow-up
Myocardial revascularization must be accompanied by medi-
cal therapy and other secondary prevention strategies for risk
factor modiﬁcation and permanent lifestyle changes (Table 26).
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